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SoC and SoC alone gained 0.3155 QALYs and 0.2752 QALYs, respectively. Hence, 
ranolazine plus SoC resulted in an ICER of € 4,620 per QALY gained, well below the 
threshold of € 34,000 per QALY gained, that is twice the annual per capita income. 
The PSA showed that the likelihood of ranolazine plus SoC being cost-effective at 
the threshold of € 34,000 per QALY gained was 100%. ConClusions: The results 
suggest that ranolazine as add–on treatment may be a cost-effective alterna-
tive for the symptomatic treatment of patients with chronic stable angina in 
Greece.
PCV123
Cost-Utility AnAlysis of APixAbAn in the ACUte treAtment And 
PreVention of VenoUs thromboembolism in frAnCe
Stern S1, Cotte F2, Minacori R2, Gosden T3, Hamilton M4, Phatak H5, Quon P1
1Evidera, Bethesda, MD, USA, 2BMS, Rueil-Malmaison, France, 3Pfizer, Tadworth, Surrey, England, 
4BMS, Princeton, NJ, USA, 5Bristol-Myers Squibb, Princeton, NJ, USA
objeCtives: To evaluate the cost-effectiveness of apixaban vs. existing thera-
peutic alternatives (fondaparinux/VKA, LMWH/VKA, rivaroxaban, dabigatran) 
in the acute treatment and prevention of venous thromboembolism (VTE) from 
the French National healthcare insurance perspective. Methods: A cohort of 
simulated patients with VTE were placed on one of five therapeutic strategies for 
6-months and tracked over a course of 5-years in a Markov model. Modeled clinical 
events included recurrent VTE, major bleed, clinically-relevant non-major bleed, 
chronic thromboembolic pulmonary hypertension, post-thrombotic syndrome and 
death. Data on efficacy and safety were derived from a network meta-analysis. 
Medical costs of clinical events were extracted from a dedicated analysis of French 
health administrative databases and utility data were derived from literature. To 
assess the costs and benefits of extended treatment, treatment durations of 12 
and 18 months were examined in scenario analyses. Additionally, probabilistic 
sensitivity analyses that accounted for uncertainty in model parameters were 
conducted for each comparator. Results: Over treatment duration of 6 months 
at lifetime time horizon, apixaban was the dominant (less costly and more effec-
tive) alternative (6,573€ and 3.38 QALYs) compared to fondaparinux/VKA (6,621€ 
and 3.37 QALYs), LMWH/VKA (6,639€ and 3.37 QALYs), rivaroxaban (6,734€ and 3.38 
QALYs) and dabigatran (6,732€ and 3.37 QALYs). Probabilistic sensitivity analyses 
revealed apixaban was more likely to be cost-effective than all other strategies. 
Considering an extended treatment duration of 12 months, apixaban remained 
dominant versus rivaroxaban and dabigatran but cost-effective compared to fon-
daparinux/VKA (ICUR: 3,098€ /QALY) and LMWH/VKA (ICUR 2,381€ /QALY). Similar 
results were observed for treatment duration of 18 months with an increase of 
ICUR to 5,634€ /QALY and 5,083€ /QALY, respectively. ConClusions: Apixaban can 
offer substantial clinical and economic benefits over alternative therapies for 
acute and extended treatment of VTE.
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objeCtives: To conduct a systematic review on the pharmacoeconomic value of 
ranolazine vs standard-of-care (SOC) for the treatment of symptomatic chronic 
stable angina (CSA). Methods: Medline, Cochrane Library and Cost-Effectiveness 
Analysis Registry without time limits were searched. Articles in English were iden-
tified with the following keywords: cost, economic, ranolazine, ranexa, angina, 
coronary artery disease. The identified studies were independently reviewed by 
two investigators against pre-determined inclusion and exclusion criteria. The 
Quality of Health Economic Studies scale was used to assess the quality of the 
included studies. The data of selected studies were extracted onto a data extrac-
tion form and consequently were synthesized. Costing and effectiveness data for 
each comparator, incremental cost per quality-adjusted-life year (QALY) gained and 
results from sensitivity analyses were extracted. Results: Five studies containing 
evidence on effectiveness and cost of ranolazine were included in the review. Four 
of these studies assessed the cost–utility of ranolazine added to SOC compared to 
SOC alone, using decision tree or Markov models whereas one was a retrospective 
cost–comparative study. In all studies, patients were stratified according to their 
angina frequency symptoms. The analysis was conducted from a payer perspective 
in 4 studies and from the societal perspective in 1 study. The time horizon of analysis 
did not exceed the 1 year at any study. Ranolazine appeared to be cost-effective 
since it reduced the number of angina-related hospitalizations and improved qual-
ity of life with an Incremental Cost–Effectiveness Ratio (ICER) varying from € 4,000 
to € 15,000 per QALY gained. The ranolazine acquisition cost was the variable that 
mainly drove the ICER. ConClusions: The existing evidence showed that ranola-
zine is cost–effective for the second–line treatment of patients with symptomatic 
CSA, added to SOC. Further research is required to evaluate the cost – effectiveness 
of ranolazine in each angina frequency group.
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objeCtives: Cost-effectiveness analysis for secondary prevention with statins in 
Brazilian context are few and with efficacy data supported from primary RCT and 
utility values from foreign populations. Effectiveness from observational database 
and utility values from a similar population provides real world evidence. The aim of 
this study is to evaluate the cost-utility of secondary prevention with statins in fatal 
and non-fatal events based on real world data. Methods: A cohort markov model 
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objeCtives: This evaluation aimed to assess the cost-effectiveness of edoxaban 
60mg versus warfarin for the prevention of stroke and systemic embolic events 
among patients with non-valvular atrial fibrillation (NVAF) in the UK, from the 
perspective of the NHS. Methods: A Markov model was developed to simulate 
the course of disease in hypothetical cohorts of patients with NVAF and to assess 
the cost-effectiveness of edoxaban versus the current UK standard of care, warfa-
rin. The model used data from the ENGAGE study, and was based on patients with 
CHADS2 ≥ 2. Utility values were derived from systematic literature reviews. Costs 
were extracted from the literature and the NHS reference cost database; both were 
discounted at 3.5% per annum. Health outcomes were assessed in quality-adjusted 
life years (QALYs), and evaluated over a lifetime time horizon. Deterministic and 
probabilistic sensitivity analyses (PSA) were conducted to evaluate the effect of 
uncertainty in input parameters on the results. Results: In the base case analysis 
(CHADS2 ≥ 2), the incremental cost-effectiveness ratio (ICER) for edoxaban compared 
with warfarin was £12,881 per QALY gained. At a threshold of £20,000 per QALY, the 
net monetary benefit associated with edoxaban was £1,406. Edoxaban was also cost 
effective compared with warfarin in higher risk (CHADS2≥ 3) and higher anticoagu-
lant control (cTTR≥ 60%) subgroups (ICER £7,012 and £20,376 per QALY, respectively). 
Sensitivity analyses support these findings, and show that conclusions are robust to 
alternative assumptions about model inputs. Starting age, edoxaban cost, monitor-
ing costs and mortality due to non-ICH major bleeds are the drivers of the results. 
PSA indicates that 82% of simulations are in the north-east quadrant of the cost-
effectiveness plane for this comparison, and that the probability that edoxaban is 
cost-effective versus warfarin is more than 50%. ConClusions: Compared with 
warfarin, edoxaban represents a cost-effective alternative for stroke prevention in 
UK patients with NVAF.
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objeCtives: Randomized controlled trials have shown favorable effects of poly-
phenols and flavonoids found in chocolate on various cardiometabolic risk factors, 
including inflammatory markers, blood pressure, lipids, and insulin sensitivity. 
Epidemiologic studies also suggest chocolate may reduce risks of cardiometabolic 
diseases. This study aims to assess the cost-utility of chocolate consumption from 
a US health system perspective. Methods: A cohort life-table analysis was devel-
oped to model life years (LYs) and quality-adjusted life years (QALYs) of chocolate 
consumption versus non-consumption over a lifetime horizon in US adults. Age- 
and sex-specific disease incidence and mortality rates were used to model outcomes 
of cardiometabolic diseases, including coronary heart disease, stroke, and diabetes. 
Relative risks of cardiometabolic disease associated with chocolate consumption 
were obtained from meta-analyses of prospective cohort and cross-sectional stud-
ies. Utility weights, baseline healthcare costs, and attributable disease costs were 
obtained from the literature. Costs of chocolate were estimated based on “high” con-
sumption, consisting of three 150mg chocolate bars per week. Outcomes included 
undiscounted LYs and discounted costs and QALYs. Incremental analyses, strati-
fied by sex, and probabilistic sensitivity analyses (PSAs) were conducted. Results: 
Chocolate consumption, compared to none, increased undiscounted LYs by 0.74 
and 0.99 years and discounted QALYs by 0.54 and 0.45 years for males and females, 
respectively. Cardiometabolic disease costs were reduced by $7,763 and $6,318 and 
total healthcare costs were reduced by $5,660 and $2,717 for males and females, 
respectively. The incremental cost per QALY for chocolate consumption was $1,482 
for males and $8,931 for females. In the PSA chocolate consumption had a 97.8% 
and 89.9% probability of being cost-effective for males and females, respectively, at 
a $50,000/QALY threshold. ConClusions: Chocolate consumption may be a cost-
effective means to reduce the risk of cardiometabolic disease. Given the limitations 
of observational study data, further research is warranted to confirm these findings.
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objeCtives: To conduct an economic evaluation comparing ranolazine plus 
standard-of-care (SoC) relative to SoC alone, in patients with chronic stable angina 
who did not respond adequately to first line therapy, in Greece. Methods: A deci-
sion tree model was locally adapted in the Greek setting to evaluate the cost-utility 
of comparators during a 6-month period. The analysis was conducted from a payer 
(sickness fund) perspective. The clinical inputs were extracted from the published 
literature. The cost inputs considered reflect drug acquisition, hospitalizations, 
vascular interventions and monitoring of patients. Resource utilization data were 
obtained from 3 local experts. All costs refer to the year 2014. Cost-effectiveness 
was assessed by means of the incremental cost per quality adjusted life year 
(QALY) saved with the ranolazine as add-on therapy, relative to SoC alone (ICER). 
Probabilistic sensitivity analysis (PSA) was performed. Results: Ranolazine as 
add-on therapy was more costly compared to SoC alone, as the 6-month total cost 
per patient was € 1,170 and € 984, respectively. Patients received ranolazine plus 
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objeCtives: People with cardiovascular disease (CVD) often require time off work 
to recover from illness or surgery (e.g. post-myocardial infarction (MI) or stroke, 
individuals incur income losses and output is reduced for employers and the wider 
economy). A systematic review was conducted to identify studies reporting the 
magnitude of these losses for European populations, for use in economic analy-
ses. Methods: A systematic search was conducted in January/February 2015 using 
Medline, Embase, the Cochrane Library, and Google, to identify studies published 
since 2004 reporting productivity losses from CVD overall or pre-defined cardio-
vascular conditions (coronary heart disease, MI, stroke, transient ischemic attack, 
angina, heart failure, peripheral artery disease, coronary revascularization). Studies 
were classified by: country; average patient or population outcomes; human capital 
or friction cost method; scope of losses (absenteeism [work days missed for illness/
recovery], presenteeism, early retirement/unemployment, premature mortality); 
CVD conditions/events. Outcomes were standardized where possible and adjusted 
to 2015 prices. Results: Twenty-five European studies were identified. Twelve 
reported population costs and one reported population productive years of life lost 
only. Monetary losses were generally assessed using the human capital (12 studies) 
rather than friction cost method (4 studies). Annual productivity losses from all CVD 
across 6 countries ranged from € 1.4 billion (absenteeism) to € 19.7 billion (premature 
mortality). One UK study reported substantially higher annual absenteeism costs 
of £9.28 billion (£3.60 billion friction-adjusted) while mortality costs were less at 
£5.23 billion. Twelve studies reported average losses from absenteeism (10 studies) 
and/or early retirement (2 studies). Inter-study variations in results reflect different 
methods and scopes, although productivity losses were substantial across different 
countries and methods. ConClusions: CVD is associated with substantially high 
CVD morbidity and mortality costs. This systematic review comprehensively docu-
ments these losses published for European populations, and is useful for populating 
economic models or burden-of-disease studies that adopt a societal perspective.
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objeCtives: Hyperkalemia can develop as a result of treatment with angiotensin-
converting–enzyme inhibitors or angiotensin-receptor blockers. This side effect is 
most common in patients with risk factors such as diabetes mellitus, heart failure, 
chronic kidney disease, or advanced age. The objective of this research was to conduct 
a systematic review on hyperkalemia caused due to angiotensin-converting–enzyme 
inhibitors. Methods: A systematic literature search for epidemiology and the burden 
of disease studies was undertaken for the databases Pubmed, Embase, Biosis, Google 
Scholar and Cochrane. Data was collected for the study type, methods, country and key 
findings. Extracted study data included hyperkalemia incidence, complications, mortal-
ity, available treatment options, as well as healthcare resource utilization and medical 
costs associated with hyperkalemia. Results: A total of 321 studies were identified 
based on the keywords. Of these, 23 studies met the inclusion criteria. Although the 
prevalence of hyperkalemia in the general population is unknown, it is present in 1-10% 
of hospitalized patients. Hyperkalemia is a common problem in patients with condi-
tions that reduce potassium excretion, especially when treated with beta-adrenergic 
blockers that inhibit Na+,K+-ATPase activity or RAAS inhibitors (RAASIs) [angiotensin-
converting-enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), mineralo-
corticoid receptor antagonists or renin inhibitors] that decrease aldosterone excretion. 
Hyperkalemia has been attributed to the use of ACE inhibitors in 10 to 38 percent of 
hospitalized patients with this complication. Hyperkalemia develops in approximately 
10 percent of outpatients within a year after ACE inhibitors are prescribed. A study sug-
gested that the mortality and morbidity from hyperkalemia as a result of combined 
treatment with ACE inhibitors and spironolactone may outweigh the potential long-
term benefits in certain high-risk patients. ConClusions: Our review shows that 
there is high burden of hyperkalemia in patients using ACE inhibitors. There is a need 
for quick, safe and effective treatments for hyperkalemia.
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objeCtives: Over one million UK patients suffer from non-valvular atrial fibrilla-
tion (NVAF), which can lead to stroke and arterial embolism. Vitamin K antagonists 
(VKA), usually warfarin, are the most frequently-prescribed anticoagulants in the UK. 
This study aimed to estimate the association between healthcare resource use and 
subsequent bleeding in NVAF patients prescribed VKA in England. Methods: A ret-
rospective cohort analysis of primary care data from the UK Clinical Practice Research 
Datalink (CPRD), linked to secondary care data from the Hospital Episode Statistics 
(HES) database, identified patients with NVAF who were prescribed a VKA. Bleeding 
events were identified (any bleeds [AB] as a composite of major bleed [MB] + clinically-
relevant non-major bleeds [CRNMB]). Resources utilised by patients (GP consultations, 
total prescriptions, hospitalisations) were estimated. To compare resource utilization 
in time after bleeding events versus time with no bleeding events, we used log-Poisson 
generalized linear models with robust variances to calculate incidence rate ratios 
(IRR) and 95% CIs adjusted on baseline patient characteristics. Results: A cohort of 
29,489 NVAF patients newly-treated with VKA were identified, with mean age of 73.4 
years, 57.8% male, mean BMI 29.1, mean CHA2DS2-VASC 2.7, and mean HAS-BLED 
2.0. Of these patients, 14.6% had experienced a prior bleeding event. Each month 
there were a mean 2.6 GP consultations, 0.1 hospitalizations, and 7 prescriptions per 
patient. We observed an increased risk of overall prescriptions following a 1st bleed 
(IRR 1.12; 1.09-1.16), 2nd bleed (1.18; 1.12-1.24) and 3rdbleed (1.25; 1.16-1.36) compared 
with five states, annual cycle and time horizon (TH) of 10 years, with discount rate of 
5% was developed. A transition probability for total cause mortality was derived from 
a administrative database of a teaching hospital after record linkage with national 
registry of mortality database and an analysis of propensity score matching. Non-
fatal endpoints were derived after a random effect meta-analysis. Utility measures 
was calculated with a validated model to derive values from published domains 
of SF-36 QoL questionnaire. Direct Costs were analyzed from the Brazilian public 
health perspective. Results: 2100 patients were propensity matched, 1050 non-
statins users (CG) and 1050 statins users (SG) with previous cardiovascular disease, 
with mean follow-up of 5 years and mean age of 60 years. Treatment effects on the 
treatment group considering all statins users reduced the total cause mortality in 0,8% 
(CI 95% -0,015%;-0,08%). ICER comparing SG with CG, in a 10 year TH, for simvastatin 
10mg, 40 mg and atorvastatin 10 mg were, USD1.657.00, USD4.431.00 and R$5.449.94, 
respectively. ConClusions: Real world evidence demonstrated that statins are less 
effective than RCT evidence to reduce all cause mortality in secondary prevention but 
with very cost-effectiveness strategy according to WHO thresholds.
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objeCtives: This evaluation aimed to assess cost-effectiveness of once-daily edoxa-
ban 60mg (30mg dose-reduced) compared with other licenced non-VKA oral anticoag-
ulants (NOACs) for prevention of stroke and systemic embolic events among patients 
with non-valvular atrial fibrillation (NVAF) in the UK. Methods: A Markov model was 
developed to simulate the course of disease and resource utilisation in a hypothetical 
cohort of patients receiving edoxaban or the other NOACs currently licensed for use in 
the UK: apixaban, dabigatran and rivaroxaban. In the absence of head-to-head clinical 
studies between NOACs, a network meta-analysis was conducted to estimate the rela-
tive efficacy and safety of edoxaban compared with all treatments of interest. Where 
data were available, the analysis was based on patients with CHADS2≥ 2; otherwise, 
the entire study population was used. Health outcomes were assessed in quality-
adjusted life years (QALYs). Utilities and costs were extracted from the literature and 
the NHS reference cost database and discounted at 3.5% per annum. Outcomes were 
evaluated over a lifetime time horizon. The average age of patients entering the model 
was 72, as in the ENGAGE-AF study. Sensitivity analyses were conducted to evaluate 
the effect of uncertainty in inputs on the results. Results: Edoxaban was dominant 
compared with rivaroxaban and dabigatran 110 mg BD. Edoxaban was dominated 
by apixaban and dabigatran 150 mg BD. Lifetime differences between edoxaban and 
comparators ranged from £394 to -£787 and 0.08 to -0.08 QALYs. Sensitivity analyses 
indicate the findings were robust. ConClusions: Accepting the limitations of mod-
elling with restricted data availability and absent head-to-head trials, this analysis 
suggests that edoxaban is associated with similar outcomes to the other NOACs in 
the UK setting. Edoxaban is dominant compared with the most widely prescribed 
once-daily NOAC, rivaroxaban. Both dabigatran and apixaban are given twice daily, 
and apixaban has a higher acquisition cost than the other NOACs.
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objeCtives: Statins are the cornerstone of cardiovascular disease prevention 
reducing individual cardiovascular risk by as much as 25% to 35%. One reason for 
interrupting statin therapy is statin-induced myopathy. Myopathy is a general term 
for muscular skeletal disease that can range from muscle pain to rhabdomyoly-
sis. The incidence rate of statin-induced myopathies has been reported to range 
from 10% to 20%. The objective of the present study was to evaluate the economic 
value of a pharmacogenomic (PGx) test for the diagnosis of statin-induced myopa-
thy. Methods: We developed a Markov model to investigate the economic value of 
a PGx test to diagnose statin-induced myopathy from the perspective of the Ministry 
of Health. The model assumes that only patients who experienced muscular skeletal 
pain (MSP) are tested and that patients and physicians are fully compliant to the 
test results. For simplification purposes, we assumed that, without a PGx test, all 
patients experiencing MSP interrupt their statin. The cost of the PGx test is assumed 
at $250. Results: The results of the model show that the PGx test is a dominant 
strategy with a perfect test and remains nearly cost neutral with an imperfect PGx 
test having 20% of false positive and false negative rates (i.e., incremental cost of 
$85) yielding an incremental cost-utility ratio (ICUR) of $451 per quality-adjusted 
life year (QALY). Deterministic sensitivity analyses show that the most influential 
model parameters are associated with statin efficacy. The results of the probabilistic 
sensitivity analysis show that at a willingness-to-pay of $5,850 per QALY, 90% of the 
model simulations favor the PGx test strategy. ConClusions: The model shows 
that a PGx test for the diagnosis of statin-induced myopathy in patients with MSP 
having ≤ 20% of false positive and false negative test results, is an optimal strategy 
at all accepted conventional willingness-to-pay ICUR thresholds.
PCV128
systemAtiC reView of ProdUCtiVity losses AssoCiAted with 
CArdioVAsCUlAr diseAse in eUroPe
Gordois AL1, Proudfoot EM1, Paoli CJ2, Gandra SR2
1Covance Market Access Services Inc., Sydney, Australia, 2Amgen, Inc., Thousand Oaks, CA, USA
